Yeah, its a bit odd that now on the website they had two PRs about nutritional supplements, which to me is more or less pointless right now. Only thing that will pop this share price is cancer and or COVID moving to phase 1. Right now only retail investors can buy shares and something in that vein of news should be enough to get retail to buy up to the dollars range. Then we can do a minimal ratio r/s, hit the Nasdaq and then get the $23 million from Aegis and any other big time investors.
It's kind of go time now, and what has me nervous is that this will be the third year straight they have reverse split the stock, and they haven't released any news beyond pre clinical studies. Yet they are throwing out a bunch of PR that no one is really here for. I mean, if the other stuff pans out down the road that's icing on the cake, but we need cancer and COVID to phase 1 human testing if this stock is going to go anywhere. Otherwise I see another year where they may reverse split the stock. Both previous times the stock plummeted shortly after.
News 
Market Data 
Discover 
